FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious <i>BRCA</i>-Mutated Metastatic Castrate-Resistant Prostate CancerMitchell S. Anscher, Julia A. Beaver, Oluseyi Adeniyi et al.|The Oncologist|2020Cited by 74
U.S. FDA Drug Approvals for Breast Cancer: A Decade in ReviewShaily Arora, Julia A. Beaver, Preeti Narayan et al.|Clinical Cancer Research|2021Cited by 73
U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in ReviewShaily Arora, Julia A. Beaver, Preeti Narayan et al.|Clinical Cancer Research|2021Cited by 23